Abdulla A. Damluji: Cardiovascular Outcomes with Tirzepatide Versus Dulaglutide in Type 2 Diabetes
Abdulla A. Damluji, Director of the Cardiovascular Center on Aging at Cleveland Clinic, has shared a post on X:
“Check out my latest article: Cardiovascular Outcomes with Tirzepatide Compared with Dulaglutide in Patients with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease via LinkedIn”
Title: Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes
Authors: Stephen J. Nicholls, Imre Pavo, Deepak L. Bhatt, John B. Buse, Stefano Del Prato, Steven E. Kahn, A. Michael Lincoff, Darren K. McGuire, Debra Miller, Michael A. Nauck, Hiroshi Nishiyama, Steven E. Nissen, Naveed Sattar, Govinda Weerakkody, Russell J. Wiese, Bernard Zinman, Sophia Zoungas, Jan Basile, Melanie J. Davies, Francesco Giorgino, Monika Kellerer, Linong Ji, Tamas Varkonyi, Venu Menon, Jonathan C. Broder, Alan Herschtal, David D’Alessio, Eli Lilly and Company, SURPASS-CVOT Investigators
Discover the latest in Hemostasis Today.
-
May 6, 2026, 02:58Limiaa Babikir: What Is Polyspecific DAT?
-
May 6, 2026, 02:47Karen Rollinson: Grateful to Be Connecting with so Many Families and Advocates at HFA 2026 in New Orleans
-
May 6, 2026, 02:38Moustafa Abdou: Is the Bone Marrow Examination Still the ‘Gold Standard’?
-
May 6, 2026, 02:23Khaled Musallam: When the Worlds of Thalassemia and Hemophilia Converge
-
May 6, 2026, 02:12Caitlin Raymond: How STOP-BABESIOSIS Just Rewrote 40 Years of Practice
-
May 5, 2026, 16:28Nikolay Novitski: A New Era in Cardiovascular Prevention
-
May 5, 2026, 16:23Satyam Arora: Best Abstract Award in Pediatric Apheresis at ASFA 2026 Congress
-
May 5, 2026, 16:17Hannah Omunakwe: Your Sick Child Has a Clot. Did You See That Coming?
-
May 5, 2026, 15:57Venous Thromboembolism Risk in Pregnancy and the Postpartum Period – NBCA